Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Stem Cell Therapy: Non-Invasive Neuropathy Relief
Free Download: Stem Cell Therapy for Peripheral Neuropathy (PN)
Disclaimer:
The information provided by R3 Stem Cell is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. The FDA considers stem cell therapy experimental at this point.
Any claims made on this website refer to procedures performed OUTSIDE of the USA. R3 Stem Cell has clinics in Mexico, Philippines, South Africa, Turkey, India, Pakistan.
Please fill out the form below to receive the guide
Every day, R3 Stem Cell receives inquiries worldwide from individuals asking if stem cell therapy can help with Peripheral Neuropathy (PN). Spoiler alert: It can help a lot! In this guide, we’ll go through the basics of how stem cells and exosomes work for PN, the latest research, and what to expect with a regenerative procedure.
Conventional treatments for neuropathy are often not able to regenerate and repair damaged nerves significantly. For those who desire reduced pain along with improved balance and sensation, failure with conventional treatments is disappointing and no improvements have been seen for a long time.
Stem cell therapy for PN is turning out to be an excellent opportunity for individuals to achieve meaningful long term results. Let’s dig in!
Avoid surgery. Repair nerves naturally. Call R3 Stem Cell: (844) GET-STEM.
Neuropathic pain is one of the most difficult chronic pain conditions to treat and affects approximately 6% of the population and can be caused by any number of events. Word descriptor qualities of neuropathic pain that patients report are typically sharp, shooting, burning, cramping, crushing, electric, or lancinating.
The most common type of peripheral neuropathy is secondary to diabetes (type 1 or 2). Diabetic peripheral neuropathy (DPN) is a complication of diabetes that affects an estimated 50% of patients with the disease.
Despite significant advances in peripheral neuropathy treatment, safe and effective treatment options targeting neuropathic pain are lacking.
There are MANY different causes of peripheral neuropathy. Here is a list of some of the more common types
Peripheral neuropathy is characterized by progressive neuronal loss, demyelination, and damaged nerve regeneration with ultimately dysfunction of nerve fibers impairing both the autonomic and somatic divisions of the nervous system. As there are many different causes of peripheral neuropathy, most of them lead to increased oxidative stress and low-grade, chronic inflammation. When chronically seen, this leads to leads to impairment in sensory, motor, and autonomic nerves. Symptoms may include pain, numbness, tingling and loss of balance in the legs, along with loss of dexterity in the hands.
The symptoms may worsen at night, leading to difficulty sleeping. Patients may experience muscle weakness and a loss of reflexes as the disease progresses, increasing the risk of falls and injuries.
Diabetic peripheral neuropathy (DPN) is a significant contributor to diabetic foot risk. According to a study, patients with DPN and sensory deficiencies have a sevenfold more significant likelihood of developing diabetic foot ulcers than those without these conditions.
The loss of protective sensation and the lack of muscular coordination in the foot and leg that result from neuropathy raise the mechanical stress placed on the body during movement, which causes severe foot defects like claw toes or hammer toes, and twisted ankles. It is challenging to treat diabetic foot; even if the ulcer heals, the recurrence rate is 30%–40% after a year.
Learn how stem cells may ease neuropathy symptoms—call (844) GET-STEM.
Current medicinal therapies for neuropathy include tricyclic antidepressants, anticonvulsants, opioids, serotonin and norepinephrine reuptake inhibitors, and topical agents. However, none of these therapies directly target the inflammatory milieu, most have untoward side effects, and there is little consensus on the optimal regimen, with less than 30% of patients receiving adequate pain relief.
Neuropathy treatment is a real challenge for physicians. NP management primarily targets clinical symptoms instead of causative factors. Currently, available treatment options include both pharmacological and nonpharmacological approaches.
Regarding pharmacological therapies of NP, tricyclic antidepressants (e.g., amitriptyline, nortriptyline), serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine and venlafaxine), and gabapentinoids (i.e., gabapentin and pregabalin) are recommended as first-line drugs.
Weak opioid analgesics, such as tramadol, are recommended as second-line drugs. Topical medications (such as lidocaine plaster and capsaicin patch) are recommended as second-line pharmacological treatments. As third-line drugs, strong opioids, such as morphine and oxycodone, are used.
Compliance with anti-neuropathic medication can be problematic for patients with potential side effects of weight gain, drowsiness, dry mouth, negative mood changes, and increased suicide risk.
Nonpharmacological treatment options for drugrefractory neuropathic pain include the following approaches: Interventional therapies (e.g., peripheral nerve blockade, epidural steroid injection, sympathetic nerve/ganglion blockade, intrathecal morphine delivery, and peripheral and central neurostimulation), physical therapies (e.g., massage, ultrasound, transcutaneous electrical nerve stimulation), and psychological therapies, such as cognitive behavioral therapy.
Spinal cord stimulation (SCS) or dorsal column stimulation constitutes an advanced neuromodulation procedure enabling to potentially decrease of neuropathic pain in many syndromes, such as in failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS) type I and II, postherpetic neuralgia, and pure radicular pain. Facial neuropathic pain is particularly difficult to treat. It responds poorly to opioid and over-the-counter analgesics. First-line anti-neuropathic medication for facial pain typically utilizes tricyclic antidepressants and anticonvulsants, with only about 25% responding.
Call (844) GET-STEM.
Stem cell therapy for peripheral neuropathy is expected to have a transformative influence in the future and provide patients with this crippling ailment with new hope. Stem cell therapy demonstrates potential for treating the root causes of the condition, fostering nerve regeneration, and easing peripheral neuropathy symptoms.
The capacity for regeneration offered by stem cell therapy is one of its most significant advantages. The ability of stem cells to encourage nerve regeneration and return to normal function is feasible by administering stem cells to the damaged areas. Patients with diabetic peripheral neuropathy, for example, have had encouraging improvements in nerve conduction, pain relief, and sensory function due to pre-clinical and early-phase clinical research.
Over the last decade, stem cell transplantation has exhibited remarkable potential for the repair of nervous system damage in neuropathic syndromes rather than simply providing temporary palliation.
The molecular mechanisms through which mesenchymal stem cells (MSCs) exert their beneficial effects with regard to pain are yet to be clarified. However, a previous study reported that MSCs migrated to injured tissue and mediated functional recovery following brain, spinal cord, and peripheral nerve lesions, suggesting that these cells could modulate pain generation following nerve constriction. Further, transplanted stem cells have been demonstrated to ameliorate disease symptoms through the integration of new graft-derived cells, which provide trophic support to endogenous cells and facilitate immunomodulation.
In addition to that, MSCs show their immunomodulatory effects via secreted cytokines and growth factors via direct cell interactions, as well as strong paracrine influences. MSCs secrete biological factors via extracellular vesicles (i.e. exosomes), which are divided into microvesicles (>200-nmdiameter) and exosomes (50–200 nm diameter). Extracellular vesicles are composed of thousands of proteins, messenger RNA, and/or microRNA, many of which are reported to enhance neuronal growth and health in model systems.
Researchers at Nanyang Medical College in China performed a double-blind, randomly paired trial with inclusion criteria of type 2 diabetes and neuropathy. 112 patients were divided into the control group (n=56) and the observation group (n=56). The observation group was administered bone marrow mesenchymal stem cells (dose not reported). The symptom effective rate, average limb nerve conduction velocity, and clinical symptom score were associated with an improvement in the observation group compared with the control group.
The symptom effective rate in the observation versus control group at 3 years was 84% (47 of 56) versus 43% (24 of 56; p<0·0001). Average limb nerve conduction velocity was 52·75 m/s in the observation group versus 41·32 m/s in the control group 3 years after treatment (p<0·0001). The clinical symptom scores in the observation group versus the control group were 4·05 versus 7·79 (p<0·0001) 3 years after treatment. There were no adverse events in control group. In both groups, no serious adverse events were reported.
The authors concluded that patients given stem cell transplantation in addition to standard treatment for diabetic peripheral neuropathy were associated with an improved average limb nerve conduction velocity and clinical symptom scores compared with those on standard treatment alone.
Riad et al published their findings in 2023 on 10 Egyptian patients with diabetic peripheral neuropathy (DPN) who were between the ages of 33 and 45, had type I or type II diabetes. They had DPN confirmed by diagnostic testing and nerve conduction, and had not received therapy for DPN. The stem cells were obtained from the patient’s own bone marrow, and then injecting 1 million MSCs/kg into the patients in one session (IV infusion). Follow-up evaluations were done after 3 months and included clinical examination, laboratory tests, and nerve conduction studies.
Results showed that all patients exhibited improvement in at least one symptom post-transfusion. Laboratory analysis revealed significant differences in hemoglobin, glucose, and cholesterol levels at 90 days post-transfusion compared to baseline levels. Nerve conduction studies revealed that most improved after MSC transfusion. Overall, the results suggest that MSC transfusion may be a promising therapeutic option for patients with diabetic peripheral neuropathy. In addition to evaluating clinical symptoms, the study also assessed laboratory test results at baseline and 90 days post-MSC transfusion. The results showed a significant improvement in levels of hemoglobin, fasting and post- prandial glucose, and cholesterol at the 90-day follow-up period compared to baseline.
These findings are consistent with previous research, which has suggested that MSC transfusion may be effective in managing intractable pain and improving neurological function through neurorestorative mechanisms, including neuroconstructive interventions, immunomodulation, and microcirculation enhancement.
In the table below, you can see the outcomes of ten randomized and controlled clinical trials on the effectiveness of stem cells for diabetic neuropathy and diabetic foot. Ulcers healed well, balance and sensation improved, along with walking ability. Circulation improved dramatically as well.
With regard to diabetes, MSCs improve glycemic control, accompanied by improved renal function and regeneration of normal β pancreatic islets. MSCs secrete neurotrophic and angiogenic factors to ameliorate diabetic neuropathy (DN), and offer a novel therapeutic option to treat DN. MSCs modulate the central nervous system-injured environment and promote repair as they secrete anti-inflammatory, antiapoptotic molecules, and trophic factors to support axonal growth, immunomodulation, angiogenesis, remyelination, and protection from apoptotic cell death.
MSCs are known to support angiogenesis mostly through a paracrine effect, which augments the microcirculation supporting peripheral nerves. This impaired vascular supply has been implicated in the lead-up to DN.
Reduce neuropathy symptoms with regenerative care—call (844) GET-STEM.
In a stem cell therapy study for trigeminal neuralgia, ten subjects (all females) were recruited for the procedure with a mean age of 55 years.
No subject showed any side effects of the treatment, which included local injections. There was no evidence of unusual localized swellings or lesions at any of the injection sites (n=36 intraoral sites and n=5 facial sites) nor evidence of general or medical health issues at any follow-up stage (to 6 months).
The results showed a reduction in pain intensity scores from the stem cell treatment in 7/9 patients (two with marginal improvement and five subjects with good-to-excellent pain reduction). Five of these positive responders also reduced their need for gabapentin medication, three required the same level of medication, and one subject commenced multiple medication trials within the 6-month period without any pain relief, with all medication subsequently discontinued.
The majority of subjects, however, reported a positive effect from stem cell therapy with pain reduction in addition to lowering anti-neuropathic medication dose to enable an improved quality of life with fewer drug side effects. Seven out of nine overall had positive responses.
Stem cells and exosomes act in the body through several mechanisms. They do NOT become part of a patient’s DNA, which means they do not engraft into the person’s existing cells.
They act through:
Angiogenesis
provokes formation of new blood vessels.
Reduce inflammation
PN is associated with significant inflammation, and the regenerative biologics reduce it nicely.
Immune system modulation
the stem cells and exosomes modulate the immune system very differently than steroids. Instead of blanketly suppressing the immune system, the regenerative biologics tamp down the harmful processes while amping up the beneficial ones. This includes ramping up production of several helpful growth factors and cytokines, while tamping down harmful ones.
Cellular signaling
the biologics are able to perform “cell-to-cell” communication. This promotes recipient cells to proliferate their growth factor production, protein production and regenerate nerve tissues that are damaged.
Prevent cell death
most cells have a timed death, where they are only allowed to live a certain length of time. This is called apoptosis. The regenerative biologics allow normally functioning cells (i.e. neuron cells) to live longer, and spare them from the pre-programmed death.
Preventing scar tissue
Once that scar tissue forms, it becomes nonfunctional. Stem Cells and exosomes are great at preventing scar tissue (anti-fibrosis).
Stem Cells can also release a huge variety of molecules into the extracellular environment. These molecules, which include extracellular vesicles (exosomes), lipids, free nucleic acids, and soluble proteins, exert crucial roles in repairing damaged tissue. Along with offering stem cells for treatment of PN, R3 Stem Cell includes stem cell exosomes, which are a type of extracellular vesicle participating in extensive cell-to-cell communication for ovarian tissue repair and regeneration.
The stem cells administered by R3 are not the ones that become a patient’s new follicle. The administered mesenchymal stem cells are not specifically designed to replace damaged and lost follicles, but rather coordinate and enhance an ovarian repair response by one’s own mechanisms.
Where do the stem cells and exosomes come from?
R3 Stem Cell’s regenerative biologics originate from umbilical cord tissue that has been donated after a scheduled c-section. No baby (or mother) is harmed during the C-section procedure. The umbilical cord tissue is normally discarded, but if the mother passes the screening test, then the umbilical cord is immediately sent to the lab.
The lab carefully processes the umbilical cord to generate large amounts of stem cells and exosomes that are of the highest quality possible. The lab team consists of multiple PhD’s working in ISO Certified, cGMP compliant clean rooms to ensure quality assurance that exceeds USA FDA standards. The proprietary production process combines the highest potency, safety and affordability for providers to confidently offer exosome procedures.
Millions of dollars have been invested in the pharmaceutical grade production of the biologics including first-rate clean rooms, bioreactors, nano-particle tracking analyzers, cytometers, PCR, tangential flow machines and real-time environmental monitoring. The quality assurance testing complies with screening and testing stan¬dards consistent with the American Association of Tissue Banks, cGMP standards, FDA regulations and the highest level of any regulatory agency globally.
Stem Cell Derived Exosomes R3 Stem Cell’s Centers of Excellence globally include umbilical cord stem cell derived exosomes with umbilical cord stem cells to provide enhanced results. Exosomes are lipid bound vesicles (acellular) produced by cells that contain a plethora of growth factors, cytokines, mRNA and other proteins.
They are exceptionally helpful in cell-to-cell communication, and very effective for reducing inflammation when they become ingested by their recipient cell. They act as shuttles to send nucleic acids and proteins to other cells, in this way, allowing cell-to-cell communication and transporting molecules among both close and distant cells. In general, these released proteins are important regulators of intracellular information.
Exosomes could be the mediators of many stem cell-associated therapeutic activities. Considering they are 100 times smaller than stem cells, they do not have any issues passing through the blood-brain barrier to reach the brain from the bloodstream.
Is stem cell therapy safe?
After a decade of performing over 24,000 stem cell procedures worldwide, R3 knows that the regenerative procedures are safe. The quality control employed during the stem cell production is second to none, and the side effects R3 sees are usually mild to moderate and temporary.
They may include itching, dizziness, lightheadedness, low grade fever, chills, headache, nausea. These are typically temporary. If a patient has an allergic reaction to the multivitamin or a preservative, all of R3’s Centers have the medications to resolve it quickly.
One of the questions we get asked a lot is, “Will the stem cells get rejected?” The answer is NO.
MSCs do not express major histocompatibility complex (MHC) antigens of the class II subtype and contain low levels of MHC molecules of the class I subtype. MSCs also lack the costimulatory molecules essential for immune detection, including CD40, CD80, and CD86.
Therefore, MSCs generally have low immunogenicity and can avoid immune rejection by the recipient, which serves as the foundation for their successful application without needing to match the donor to the recipient. Scientists call this being “immunologically privileged”.
Another question often asked is “Is there a chance of a tumor forming?” Once again the answer is NO. The mesenchymal stem cells and exosomes used during treatment have never been shown to have tumor-forming potentials. In fact, they have been shown to be anti-tumor forming.
Explore stem cell therapy for peripheral neuropathy. Call (844) GET-STEM.
Treatment Protocol
For the past decade, R3 has been successfully treating patients with stem cell and exosome therapies with injection, infusion, intranasal, intrathecal and nebulizer procedures. For Peripheral Neuropathy, R3’s providers use between one and three million stem cells per kilogram (depends on patient weight). In addition, billions of stem cell exosomes and platelet rich plasma therapy (PRP) are included at no cost.
R3 Stem Cell’s PN treatment protocol includes an IV therapy combining mesenchymal stem cells and exosomes, along with a multivitamin IV as well. R3 has developed a proprietary injection protocol for the legs combining the biologics along with platelet rich plasma therapy to increase the effectiveness of the therapy. Safety is paramount with the biologics products being rigorously tested prior to use, and expert providers managing each treatment as if you were a family member!
Why does R3 Stem Cell use donor tissue for its stem cells?
Although autologous (your own) stem cells provide significant advantages, allogeneic (donor) stem cells have more advantages. First of all, autologous MSCs need a long time to culture and expand, which limits its application in treatment, while allogeneic stem cells can be obtained and expanded more quickly, thus avoiding the delay of time window.
Second, age is a factor that affects the physiological characteristics of MSCs. Studies have shown that stem cells from elderly donors have decreased proliferation and differentiation ability. This means they are less in number and less effective!
Affordability
Stem cell therapy for PN may be the key step to completely changing a person’s quality of life, and we want to make it affordable for as many individuals as possible. Our global volume has allowed us to keep our patient cost as low as possible.
Unfortunately, stem cell clinics in Colombia, China and Panama charge over $20,000 USD for PN treatment. How are individuals supposed to budget for that?? R3 Stem Cell’s fees are typically less than half that for full treatment, which also includes free exosomes, PRP and a multivitamin infusion!
R3’s Experience
For the past decade, R3 Stem Cell’s Centers globally have performed over 24,000 regenerative procedures in six countries. Patient satisfaction across all conditions treated is very high, at 85%. R3 has treated hundreds of patients with varying types of peripheral neuropathy, and over a thousand patients with diabetes.
R3 combines safety, effectiveness and affordability for the therapies. Internationally, the Intellicell is used, which is culturing the most active mesenchymal stem cells to create the “smartest” stem cell in the world!
R3 Stem Cell offers free consultations for individuals to discuss whether regenerative therapy is indicated for your PN. Simply call (844) GET-STEM to schedule yours!
References
David Greene, MD, PhD, MBA, Founder/CEO
R3 Stem Cell offers treatments that bring patients hope and options. Hope that surgery can be avoided, and tissue injury can be repaired with patients being able to get back to desired activities.
Founder and CEO David Greene, MD, PhD, MBA writes extensively on regenerative medicine and gives many seminars worldwide on a regular basis. With over forty Centers of Excellence globally, R3 is at the forefront of regenerative therapies.
R3’s Centers have successfully performed over 24,000 regenerative procedures to date. Call today for your free consultation (844) GET-STEM!
No portion of this document may be reproduced without the Express Written Consent of R3 Stem Cell.
This guide’s education does not constitute medical advice. The USA FDA considers stem cell therapy experimental. Any claims made in the Guide refer to procedures performed outside the USA.
Brand Ambassador Gallery
The USA stem cell leader offers procedures in
7 Countries including:
SUCCESS STORIES
R3 STEM CELL MASTER CLASS
Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!
R3 STEM CELL INTERNATIONAL
R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.
FREE STEM CELL CONSULTATION
R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.
PROVIDER PARTNERSHIP
The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!
R3 Stem Cell is a global leader in regenerative medicine, offering advanced stem cell and exosome therapies through Centers of Excellence in over 45 locations across 7 countries. Our mission is to provide first-rate, customized regenerative treatments, including stem cells, exosomes, PRP, vitamins, and peptides, to help patients achieve a better quality of life. With more than 26,000 procedures performed and an 85% patient satisfaction rate, our experienced, compassionate providers are committed to delivering safe, effective care. All therapies are nonsteroidal, outpatient procedures designed to harness the body’s natural repair mechanisms and support tissue regeneration. Individual results may vary, and only your medical professional can explain all the risks and potential benefits of any therapy based on your unique circumstances.
Stem cell therapy is considered experimental and is regulated by the U.S. Food and Drug Administration (FDA), but it is not FDA-approved. R3 Stem Cell does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.
CALIFORNIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEBRASKA
NEW JERSEY
NEW YORK
NEW MEXICO
NEVADA
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
Disclaimer: The city links above provide general information on stem cell treatment. To find an R3 Stem Cell clinic near you click here
The USA stem cell leader offers procedures in
7 Countries including:
Copyright © 2017-2025 R3 Stem Cell. All Rights Reserved.
